NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading DNLI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Manage financial obligations including new direct obligations: metric not reported.
View ThesisRevenue is contracting — down about 100% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 44%, softest on returns on capital.
View QualityManagement screens strong on earnings delivery.
View ManagementModerate volatility — typically moves about 2% a day.
View RiskDNLI's growth depends on managing financial obligations while improving its performance. Recent financial results have been steady but below industry peers. The stock trades at a typical valuation compared to its peers. This suggests the price reflects the expected growth. If DNLI cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 26% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. DNLI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering DNLI (as of Jul 2026).
Based on 4 Wall Street analysts offering 12-month price targets for DNLI in the last 4 months.
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Deliver first TV-enabled medicine in 2026
Approval news supports timeline for TV-enabled medicine.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $23.02
The last 12 months of price, then the range of analyst 12-month targets from today’s $23.02.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Deliver first TV-enabled medicine in 2026
Positive update on clinical study aligns with product objectives.
